stockrowArcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
Follow RCUS
Alert me
Arcus Biosciences, Inc. (RCUS) Book value per share
Arcus Biosciences, Inc.'s book value per share at the end of fiscal 2025 was 5.9×, up 9.15% from 5.4× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 2.8×. Over the past ten years it has ranged from 0.0× (fiscal 2016) to 84.2× (fiscal 2017); the current reading is higher than 40% of that period. Arcus Biosciences, Inc. ranks 227th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 5.9× | 9.15% |
| FY2024 | 5.4× | (13.78%) |
| FY2023 | 6.2× | (31.58%) |
| FY2022 | 9.1× | (24.90%) |
| FY2021 | 12.2× | 32.55% |
| FY2020 | 9.2× | 145.18% |
| FY2019 | 3.7× | (44.91%) |
| FY2018 | 6.8× | (91.94%) |
| FY2017 | 84.2× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 2.8× | (23.63%) |
| Jun 2026 | 3.7× | (11.94%) |
| Mar 2026 | 4.2× | (28.88%) |
| Dec 2025 | 5.9× | 43.51% |
| 36 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| IDYA IDEAYA Biosciences, Inc. compare | 10.6× |
| BEAM Beam Therapeutics Inc. compare | 9.1× |
| MBX MBX Biosciences, Inc. compare | 8.6× |
| XNCR Xencor, Inc. compare | 6.6× |
| PHVS Pharvaris N.V. compare | 5.1× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 5.1× |
| RCUS Arcus Biosciences, Inc. | 2.8× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 1.7× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on RCUS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement